SEER Stock Overview A life sciences company, engages in developing and commercializing products to decode the biology of the proteome. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Seer Historical stock prices Current Share Price US$2.31 52 Week High US$2.63 52 Week Low US$1.51 Beta 1.59 1 Month Change -4.94% 3 Month Change 32.00% 1 Year Change 26.92% 3 Year Change -90.28% 5 Year Change n/a Change since IPO -95.91%
Recent News & Updates
Insufficient new directors Dec 01
Consensus EPS estimates fall by 11%, revenue upgraded Nov 13
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 08
Seer, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 18
New minor risk - Market cap size Aug 23
Consensus revenue estimates decrease by 18%, EPS upgraded Aug 15 See more updates
Insufficient new directors Dec 01
Consensus EPS estimates fall by 11%, revenue upgraded Nov 13
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 08
Seer, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 18
New minor risk - Market cap size Aug 23
Consensus revenue estimates decrease by 18%, EPS upgraded Aug 15
Seer, Inc. Appoints Nicolas Roelofs to Its Board of Directors Aug 15
Price target decreased by 57% to US$3.00 Aug 13
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09
Seer, Inc. Revises Revenue Guidance for the Full Year 2024 Aug 09
Seer, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 19
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 3000 Index Jul 03
Consensus revenue estimates fall by 11% May 15
Seer, Inc. Provides Revenue Guidance for the Full Year 2024 May 10 Seer, Inc. (NasdaqGS:SEER) announces an Equity Buyback for $25 million worth of its shares. May 09
Seer, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
We're Keeping An Eye On Seer's (NASDAQ:SEER) Cash Burn Rate Apr 27
Seer, Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 24
Founder recently sold US$107k worth of stock Mar 14
New minor risk - Shareholder dilution Mar 05
Seer, Inc. (NASDAQ:SEER) Just Reported, And Analysts Assigned A US$7.00 Price Target Mar 02
Full year 2023 earnings: EPS exceeds analyst expectations Mar 02
New minor risk - Shareholder dilution Mar 01
Seer, Inc. Provides Revenue Guidance for the Full Year 2024 Mar 01
Seer, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 02
Seer, Inc. Announces Board and Committee Changes Dec 23
Seer, Inc. Announces Management Changes Nov 18
Newsflash: Seer, Inc. (NASDAQ:SEER) Analysts Have Been Trimming Their Revenue Forecasts Nov 17
New minor risk - Market cap size Nov 12
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09
Seer, Inc. Provides Revenue Guidance for the Year 2023 Nov 08
Seer, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
Founder recently bought US$98k worth of stock Aug 27
Consensus revenue estimates decrease by 29%, EPS upgraded Aug 15
Seer, Inc. Revises Revenue Guidance for the Full Year 2023 Aug 11
Less than half of directors are independent Aug 10
New major risk - Revenue and earnings growth Aug 10
Price target decreased by 25% to US$6.67 Aug 09
Seer, Inc. Announces the Resignation of Mostafa Ronaghi as Member of the Company's Board of Directors Jul 23
Seer, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 14
We're Not Very Worried About Seer's (NASDAQ:SEER) Cash Burn Rate May 19
First quarter 2023 earnings: EPS in line with expectations, revenues disappoint May 11
Seer, Inc. Provides Earnings Guidance for the Year 2023 May 10
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 03
Founder recently sold US$57k worth of stock Feb 27
Seer, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 10
Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth Feb 06
Executive VP recently sold US$124k worth of stock Dec 12
Price target decreased to US$10.00 Nov 16
Analysts Have Lowered Expectations For Seer, Inc. (NASDAQ:SEER) After Its Latest Results Nov 11
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Seer, Inc. Provides Revenue Guidance for the Full Year 2022 Nov 09
Seer, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 14
Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans Sep 15
Omead Ostadan Resigns as President of Seer, Inc. and from Its Board of Directors Aug 27
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 10
Seer, Inc. Provides Earnings Guidance for the Full Year of 2022 Aug 10
Seer stock tumbles aftermarket despite in-line Q2 earnings Aug 09
Seer, Inc. Launches First-Of-Its-Kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0 Aug 04
Seer, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 15
Seer, Inc.(NasdaqGS:SEER) dropped from Russell 2000 Growth Index Jun 26
General Counsel & Secretary recently sold US$73k worth of stock Jun 12
Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth Jun 02
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 06
Seer, Inc. Provides Revenue Guidance for the Full Year 2022 May 05
Part Time President recently sold US$530k worth of stock Apr 27
Part Time President recently sold US$530k worth of stock Apr 24
Seer, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 08
Consensus forecasts updated Mar 08
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 03
Seer, Inc. Provides Earnings Guidance for the Full Year 2022 Mar 02
Seer, Inc. Announces Returning of its President and Chief Operating Officer, Omead Ostadan from Previously Announced 3 Month Leave of Absence Feb 19
Executive VP & Chief Financial Officer recently sold US$51k worth of stock Feb 09
Seer, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 02
We Think Seer (NASDAQ:SEER) Can Afford To Drive Business Growth Jan 17
Seer Announces Broad Commercial Release of the Proteograph™ Product Suite Jan 12
Price target decreased to US$48.67 Jan 08
Consensus forecasts updated Jan 07
President notifies of intention to sell stock Dec 20
Executive VP & Chief Financial Officer exercised options to buy US$699k worth of stock. Dec 13
Executive VP & Chief Financial Officer recently sold US$532k worth of stock Dec 13
President exercised options and sold US$556k worth of stock Nov 23
Less than half of directors are independent Nov 15
Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.79 loss in 3Q 2020) Nov 12
Executive VP & Chief Financial Officer exercised options and sold US$351k worth of stock Nov 06
President exercised options and sold US$605k worth of stock Oct 22
Executive VP & Chief Financial Officer exercised options and sold US$311k worth of stock Oct 09
President notifies of intention to sell stock Sep 21
Seer: First Pick In Proteomics Portfolio Sep 18
Executive VP & Chief Financial Officer exercised options and sold US$369k worth of stock Sep 04
Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans Aug 30 Shareholder Returns SEER US Life Sciences US Market 7D -6.5% -2.1% -2.4% 1Y 26.9% -5.5% 23.4%
See full shareholder returns
Return vs Market: SEER exceeded the US Market which returned 23.3% over the past year.
Price Volatility Is SEER's price volatile compared to industry and market? SEER volatility SEER Average Weekly Movement 6.6% Life Sciences Industry Average Movement 9.2% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SEER has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SEER's weekly volatility (7%) has been stable over the past year.
About the Company Founded Employees CEO Website 2017 147 Omid Farokhzad seer.bio
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
Show more Seer, Inc. Fundamentals Summary How do Seer's earnings and revenue compare to its market cap? SEER fundamental statistics Market cap US$136.21m Earnings (TTM ) -US$82.66m Revenue (TTM ) US$14.61m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SEER income statement (TTM ) Revenue US$14.61m Cost of Revenue US$7.58m Gross Profit US$7.03m Other Expenses US$89.69m Earnings -US$82.66m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.40 Gross Margin 48.13% Net Profit Margin -565.83% Debt/Equity Ratio 0%
How did SEER perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 05:30 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Seer, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Derik de Bruin BofA Global Research Tycho Peterson J.P. Morgan Rachel Vatnsdal Olson J.P. Morgan
Show 4 more analysts 
